News

November 14, 2017

Upstream Medical Technologies closes bridging capital raise round

Upstream Medical Technologies Ltd, has just closed a bridging round fully subscribed and over subscribed.

With the successful close of the bridging round, Upstream is poised to focus on a Series A capital raise aimed at securing funds for an international multicentre clinical trial for its lead unstable angina test, UA Score. This will provide the regulatory approvals and further clinical validation for commercialising UA Score.

See attached press release here

‍

Share this post

More Articles

Detecting at-risk heart attack patients, a step closer with $2m investment

Upstream Medical Technologies, a leading deep-tech company focused on developing innovative solutions for heart disease, announced today that it has closed a significant capital round to further advance its frontline diagnostic tests for cardiac diseases.

Upstream commences testing Marker C on the APACE cohort

The next phase of development is now underway, with the commencement of testing Marker C on the APACE cohort.

December 12, 2022

Analysis of Marker C in clinical triage protocols available

By shifting chest pain patients with intermediate troponins to low or high-risk categories, Marker C could rapidly triage 10-35% more chest pain patients in the emergency department.

Connect with us

info@upstreamdx.com

Auckland, New Zealand